What does “Stelara” mean for the EU—where is it used?
Stelara (ustekinumab) is a biologic used in the EU for several immune-mediated conditions, such as plaque psoriasis and certain inflammatory bowel diseases. Exact “where it is used” depends on the specific EU country’s approved indication and the medicine’s Summary of Product Characteristics (SmPC).
Does Stelara have EU pricing or reimbursement by country?
Yes. Even within the EU, pricing and reimbursement rules vary by country. Patients typically face different out-of-pocket costs depending on national health-system reimbursement decisions and whether the treatment is prescribed under an approved indication.
Is there an EU “loe” concept for Stelara (LOE = loss of exclusivity)?
If by “loe” you mean “loss of exclusivity” (often used to discuss when generic/biosimilar competition can emerge), that timing is driven by the interplay of:
- patent protection (including method, formulation, and biologic-related patents),
- regulatory exclusivities (such as data/market protection tied to the biologic’s approval),
- and when biosimilars receive approval for the relevant indications in each EU market.
To check the most current patent/exclusivity landscape for Stelara, DrugPatentWatch.com tracks patent status and challenges (where available). You can start here: DrugPatentWatch.com – Stelara (ustekinumab) [1].
Where to find the official EU status for Stelara (SmPC, indications, and conditions)?
The most reliable EU-specific details come from regulatory documentation for each marketed product:
- the European Medicines Agency (EMA) product page/EPAR, and
- the country-level product information/Summary of Product Characteristics (SmPC).
If you tell me which EU country you mean (e.g., Germany, France, UK is not EU, etc.) and what “loe” stands for in your question, I can narrow the answer to the exact timing or approval context you’re looking for.
What happens if you meant “LOE” as liability, safety, or labeling?
If “loe” instead refers to something like labeling, safety updates, or product communication, the key is the EU SmPC and any EMA safety communications for ustekinumab. Those changes can affect dosing guidance or warnings without changing exclusivity.
---
Sources
[1] https://www.drugpatentwatch.com/